SCHEMBL3020360

SCHEMBL3020360

CC(C)CCCC(O)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 3/20 0.58
FFAR1 O14842 1/20 0.58
BLM P54132 1/20 0.56
TET2 Q6N021 3/20 0.48
KDM4A O75164 2/20 0.48
KDM4C Q9H3R0 2/20 0.48
KDM2A Q9Y2K7 2/20 0.48
TET3 O43151 1/20 0.48
OR51E2 Q9H255 1/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
SLC1A3 P43003 1/20 0.38
SLC1A2 P43004 1/20 0.38
SLC1A1 P43005 1/20 0.38
CA1 P00915 1/20 0.37
TBXAS1 P24557 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16428981 1.00 GPR84 (0.58) GPR84FFAR1BLMTET2KDM4A
SCHEMBL14661633 1.00 GPR84 (0.58) GPR84FFAR1BLMTET2KDM4A
SCHEMBL28704367 0.95 GPR84 (0.64) GPR84FFAR1BLMTET2KDM4A
SCHEMBL9446362 0.93 GPR84 (0.68) GPR84FFAR1BLMTET2KDM4A
SCHEMBL22634111 0.93 GPR84 (0.68) GPR84FFAR1BLMTET2KDM4A
SCHEMBL4626344 0.93 GPR84 (0.68) GPR84FFAR1BLMTET2KDM4A
SCHEMBL6555168 0.93 GPR84 (0.68) GPR84FFAR1BLMTET2KDM4A
SCHEMBL28615741 0.93 GPR84 (0.68) GPR84FFAR1BLMTET2KDM4A
SCHEMBL6037095 0.93 GPR84 (0.68) GPR84FFAR1BLMTET2KDM4A
SCHEMBL27780074 0.93 GPR84 (0.68) GPR84FFAR1BLMTET2KDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0007785-A2 Skin treatment compositions, process for their preparation and applicator containing these compositions UNILEVER PLC (GB) 1980-02-06 EP claimed
US-12053465-B2 KCC2 expression enhancing compounds and uses thereof WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2024-08-06 US disclosed
US-20220378782-A1 KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2022-12-01 US disclosed
US-11331313-B2 KCC2 expression enhancing compounds and uses thereof WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2022-05-17 US disclosed
US-20200085817-A1 KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2020-03-19 US disclosed
WO-2020039768-A1 POLYMER PRODUCTION METHOD 東亞合成株式会社 2020-02-27 WO disclosed
WO-2018217766-A1 KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2018-11-29 WO disclosed
US-20150038333-A1 PLANT PROTECTIVE COMPOSITION CONTAINING ALPHA-HYDROXY ACIDS HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENT -RUN FÜR GESUNDHEIT UND (DE) 2015-02-05 US disclosed
EP-2736331-A1 PLANT PROTECTIVE COMPOSITION CONTAINING ALPHA-HYDROXY ACIDS Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) 2014-06-04 EP disclosed
WO-2013014245-A1 PLANT PROTECTIVE COMPOSITION CONTAINING ALPHA-HYDROXY ACIDS HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) 2013-01-31 WO disclosed
US-6197343-B1 GRANULES AND BLOOD CIRCULATION ACCELERATION FOR SKINS KAO CORPORATION (JP) 2001-03-06 US disclosed
US-6063366-A WATER INSOLUBLE PARTICLES IN BINDER KAO CORPORATION (JP) 2000-05-16 US disclosed
EP-0965328-A1 COSMETIC Kao Corporation (JP) 1999-12-22 EP disclosed
EP-0904772-A1 SKIN COLOR IMPROVER Kao Corporation (JP) 1999-03-31 EP disclosed
EP-0872228-A1 COSMETOLOGICAL METHODS Kao Corporation (JP) 1998-10-21 EP disclosed
EP-0575844-B1 Hydroxamic acid derivatives and pharmaceutical compositions thereof HOFFMANN LA ROCHE (CH) 1998-01-21 EP disclosed
CN-1165521-A Phenyl peptides, method for preparing same, and pharmaceutical compositions containing said peptides LAPHAL LABORATOIRES SA (FR) 1997-11-19 CN disclosed
EP-0575844-A2 Hydroxamic acid derivatives and pharmaceutical compositions thereof F. HOFFMANN-LA ROCHE AG (CH) 1993-12-29 EP disclosed
EP-0374097-A2 Use of peptide isosteres as retroviral protease inhibitors CIBA-GEIGY AG (CH) 1990-06-20 EP disclosed
US-4424234-A A-HYDROXYCAPROIC ACID OR A-HYDROXYCAPRYLIC ACID LEVER BROTHERS COMPANY (US) 1984-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11331313-B2 KCC2 expression enhancing compounds and uses thereof MECP2, SLC1A2, GRIN2C GPR84 791/4885FFAR1 3759/4885BLM 2534/4885
US-20200085817-A1 KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF MECP2, SLC1A2, GRIN2C GPR84 791/4885FFAR1 3759/4885BLM 2534/4885
US-20220378782-A1 KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF MECP2, SLC1A2, GRIN2C GPR84 791/4885FFAR1 3759/4885BLM 2534/4885
US-20150038333-A1 PLANT PROTECTIVE COMPOSITION CONTAINING ALPHA-HYDROXY ACIDS HAO1, HAAO, HAO2 GPR84 2235/4885FFAR1 197/4885BLM 3148/4885
US-12053465-B2 KCC2 expression enhancing compounds and uses thereof MECP2, SLC1A2, GRIN2C GPR84 791/4885FFAR1 3759/4885BLM 2534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.